|
KMID : 1001020200180030183
|
|
Journal of Urologic Oncology
2020 Volume.18 No. 3 p.183 ~ p.193
|
|
|
Urinary Biomarker in Bladder Cancer at Present Time
|
|
Kim Sung-Han
Lee Hyung-Ho
Seo Ho-Kyung
|
|
|
Abstract
|
|
|
|
Current standard diagnostic modality of bladder cancer is cystoscopy with/without urine cytology from patient's voided urine. Considering several cystoscopic disadvantages such as symptomatic invasiveness and operator- dependency, urinary cytology is an asymptomatic, noninvasive tool to detect exfoliated tumor cell in the urine samples. Various targeting molecules have been suggested to detect cancer cells in the urine beside the present urine cytology which has a limited diagnostic power of detection cancer cells. To augment the accuracy of diagnostic power, various supplementary urine biomarkers have been approved and under investigation in these days with different mechanisms and different targets. In this review article, we are going to discuss some urinary biomarkers approved by the U.S. Food and Drug Administration (FDA) and other non-FDA approved potential urinary markers in bladder cancer.
|
|
|
KEYWORD
|
|
|
Urinary bladder neoplasms, Urine, Marker, Sensitivity, Specificity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|